THE REAL PROBLEM
Drug prices keep falling — but API costs are hard to control
With continued government drug-price cuts and intensifying competition, Korean pharmaceutical companies are focused more than ever on reducing manufacturing costs and stabilizing supply. The active pharmaceutical ingredient (API) is the single largest component of manufacturing cost. Yet today's API distribution often passes through several intermediary layers, widening the gap between the manufacturer's actual supply price and the final purchase price.
Drug-price pressure
Cutting costs has become essential to defend margins.
API = the biggest cost
The largest share of manufacturing cost — the most direct lever.
Opaque multi-layer distribution
The gap between original and final price keeps widening.
APIXORA was built to reduce this structural inefficiency.
WHY APIXORA
Why APIXORA
Korea's pharmaceutical market faces growing cost pressure from drug-price cuts and competition. The API is the largest share of manufacturing cost, yet multi-layer distribution widens the gap between the manufacturer's supply price and the final purchase price. APIXORA was established to reduce this structural inefficiency.
Fewer distribution layers
Cut unnecessary middle layers to improve cost competitiveness.
Sourcing transparency
Open visibility into pricing, terms, and progress for sourcing closer to the original price.
Faster matching
Connect with verified suppliers quickly, by product.
WHAT IS APIXORA
One Platform, Three Connections
APIXORA is a verified global API sourcing platform that directly connects Global API Manufacturers, Global API Agents, and Korean Pharmaceutical Companies through a transparent, secure, and structured sourcing system.
Built on 20+ years in the field
APIXORA was built from firsthand understanding of:
Our mission is to build a faster, more transparent, and more efficient API business ecosystem for the future.
TRANSPARENT COMMISSION
Commission, made clear — written right into the contract
APIXORA's commission is charged to overseas manufacturers and agents; it is not charged separately to Korean pharmaceutical buyers. The commission is added to the supplier's quote as shown to the buyer, and the exact rate is stated in the supplier's contract.
- Charged to overseas manufacturers and agents, not to buyers — the rate is stated in the supplier contract
- Supply amount, commission, and total are auto-calculated and shown transparently
- Payment, settlement, and customs are handled between the parties; the platform tracks status
- Tailored supply and payment structures to match buyer requirements
APIXORA brings the trade process and documents together, but the payment itself happens outside the platform.
An escrow payment system is planned to minimize transaction risk across product delivery and payment.
Price breakdown
WHY KOREA
Why the Korean Market
Korea is one of the most advanced pharmaceutical manufacturing markets in Asia. High regulatory standards and steady API demand create stable, long-term partnership opportunities.
- Strong generic market
- Sustainable API demand
- High regulatory standards (KDMF·cGMP·ICH)
- Stable long-term supply
- Growing sourcing diversification
As Korean pharmaceutical companies continue to pursue cost optimization, direct partnerships with manufacturers are becoming more important than ever.
KDMF SUPPORT
Korean regulatory document flow, inside the platform
For overseas manufacturers and Korean pharmaceutical companies, APIXORA provides — free of charge — regulatory document review, document exchange, linked-review coordination, and MFDS supplementary-response support required for KDMF registration.
- KDMF registration document review & preparation supportReview support for DMF, GMP, WC, CoPP, manufacturing process and regulatory documents
- MFDS linked-review & supplementary-response supportSupport for manufacturer–buyer responses to MFDS queries and supplementary requests
- Unified regulatory progress trackingTrack document exchange, review status and supplementation progress in real time on the platform
APIXORA members can use KDMF registration support, linked-review response and basic regulatory consulting at no additional cost.
Better Connections. Stronger Partnerships. Built on Trust.
Connect. Source. Grow.
Join APIXORA and grow your API business in Korea.
Together, let's build the future of the global pharmaceutical industry.
Get started
Connecting Global Pharma Intelligence
Owned & Operated by Cell TheraOn
Transparent & Efficient